A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial

Abstract : Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02086876
Contributor : Laurent Jonchère <>
Submitted on : Monday, April 1, 2019 - 4:14:25 PM
Last modification on : Monday, April 8, 2019 - 3:22:22 PM

Links full text

Identifiers

Citation

Catherine Droitcourt, Sébastien Barbarot, Annabel Maruani, Laure Darrieux, Laurent Misery, et al.. A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial. Trials, BioMed Central, 2019, 20 (1), pp.184. ⟨10.1186/s13063-019-3276-9⟩. ⟨hal-02086876⟩

Share

Metrics

Record views

16